

Narcolepsy Drugs Market Size on Target to Grow \$5.36 billion by 2026

Increase in prevalence of narcolepsy globally and rise in awareness regarding the importance of early diagnosis of narcolepsy play a major role in the growth

PORTLAND, OR, UNITED STATES,
December 11, 2020 /
EINPresswire.com/ -- UPDATE
AVAILABLE ON-DEMAND

The narcolepsy drugs market was pegged at \$2.43 billion in 2018 and is projected to reach \$5.36 billion by 2026, registering a CAGR of 10.3% from 2019 to 2026.



Narcolepsy Drugs Market

Rise in the global prevalence of narcolepsy, presence of reimbursement policies regarding narcolepsy, and narcolepsy awareness programs and services have boosted the growth of the narcolepsy drugs market. However, adverse effects and risks related to narcolepsy drugs and delayed diagnosis or misdiagnosis hamper the market growth. On the contrary, untapped markets in developing countries are expected to create lucrative opportunities in the near future.

“

Narcolepsy Drug Market by Disease Type (Daytime Extreme Sleepiness, Cataplexia, & Other) & Therapeutics Type (Tricyclic Antidepressant, Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, & Other)”

Mangesh Panhale

Download Free Report Sample @
<https://www.alliedmarketresearch.com/request-sample/3612>

The market report includes a detailed analysis of the Covid-19 impact on the narcolepsy drugs market. Over the course of 2020–2027, the market is expected to show

significant growth. However, the recent Covid-19 outbreak is likely to affect some of the business operations. The report includes an analysis of how Covid-19 has and will affect the industry,

studying reliable sources, interviews of experts, and annual reports of the major market players. The report includes major drivers, restraints, and opportunities within the narcolepsy drugs market.

Narcolepsy is a chronic disabling condition with symptoms such as cataplexy, excessive daytime sleepiness (EDS), sleep paralysis, hypnogogic hallucinations, and disrupted nocturnal sleep. Most of the narcolepsy drugs are used to treat symptoms related to cataplexy and excessive daytime sleepiness.

The global narcolepsy drug market size has witnessed significant growth in the past few years, owing to rise in awareness regarding the benefits of early diagnosis of narcolepsy drug and availability of wide variety of narcolepsy drugs contribute toward the market growth. Governments of countries such as India and South Africa are promoting the awareness of importance of narcolepsy, which is further expected to boost the narcolepsy drug market growth during the forecast period. However, stringent government regulations toward the approval for novel narcolepsy drugs is projected to hamper the market growth during the forecast period. Conversely, untapped markets in the developing countries are expected to offer remunerative opportunities for the market players in the near future.

Inquire before buying @ <https://www.alliedmarketresearch.com/purchase-enquiry/3612>

Based on narcolepsy disease type, the narcolepsy drugs market is segmented into daytime extreme sleepiness, cataplexia, and others. Daytime extreme sleepiness segment is the highest revenue generator in the overall narcolepsy drugs market, as large number of people suffering from narcolepsy and other sleep disorders have a higher risk of this symptom, thus increasing the demand for narcolepsy drugs. However, the cataplexia segment is expected to grow at the highest rate, as patients suffering from cataplexia experience loss of muscle control, and almost 70% of narcolepsy patients are found to have this symptom.

Based on therapeutics type, the narcolepsy drugs market is segmented into central nervous system stimulants, tricyclic antidepressants, sodium oxybate, selective serotonin reuptake inhibitor, and others. The sodium oxybate segment held the highest share global narcolepsy drugs market in the 2018, as these drugs are highly effective to treat daytime extreme sleepiness and cataplexy. However, selective serotonin reuptake inhibitor segment is expected to grow at the highest rate due to increase in R&D activities for the development of these type of drugs by the key players.

The Major Key Players Are:

- Ligand Pharmaceuticals
- Addrenex Pharmaceuticals
- Shire Plc
- Teva Pharmaceutical Industries Ltd.

- Aren Pharmaceuticals
- Jazz Pharmaceuticals Plc
- Bioprojet
- Novartis

Access Full Report @ <https://www.alliedmarketresearch.com/narcolepsy-drugs-market>

Key Findings of the Narcolepsy Drugs Market:

- Based on disease type, the cataplexia segment is expected to experience rapid growth in the market, and is projected to grow at a highest CAGR from 2019 to 2026.
- Depending on disease type, the daytime extreme sleepiness segment holds the highest share in 2018, and is anticipated to continue this trend during the forecast period.
- By therapeutics type, the sodium oxybate segment was the major revenue contributor in 2018, and is anticipated to continue this trend during the forecast period.
- Asia-Pacific region is anticipated to grow at high CAGR during the forecast period.

Similar Reports:

[Structural Heart Devices Market Analysis and Industry Forecast, 2027](#)

[Endovascular Aneurysm Repair Market Analysis and Industry Forecast, 2027](#)

[Membrane Microfiltration Market Analysis and Industry Forecast, 2027](#)

About Us:

Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Analytics LLP

+1 800-792-5285

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/532596028>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2020 IPD Group, Inc. All Right Reserved.